Quinazoline analogs as receptor tyrosine kinase inhibitors
US7452895B2 · kind B2 · utility
13Cited by
21References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 10, 2004 |
| Grant date | Nov 18, 2008 |
| Priority date | — |
| Expiry date | Nov 13, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention provides quinazoline analogs of Formula I:where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.